Genetic Diversity of Hepatitis C Virus among Blood Donors and Patients with Clinical Hepatitis in Ibadan, Nigeria

  • J.A Shenge
  • Georgina Njideka Odaibo
  • David O Olaleye


Hepatitis C virus (HCV) infection is responsible for liver diseases and hepatocellular carcinoma in chronically-infected patients. Owing to high sequence variability in HCV genome, numerous subtypes have emerged. This study determined HCV strains among patients with clinical hepatitis and blood donors in Ibadan. Blood samples were collected from 176 individuals who tested positive to HCV IgM antibodies, including 99 patients with clinical hepatitis and apparently healthy 77 blood donors. Viral RNA was extracted from blood samples, then presence of HCVtested by amplifying the NS5B gene using polymerase chain reaction (PCR). The amplified NS5B gene was sequenced andsequences were aligned on MEGA 7.0. Phylogenetic tree was constructed with Neighbor-Joining method. Data were analyzed using descriptive statistics at P<0.05.The NS5B gene was amplified in 38 samples, of which 29 were successfully sequenced. Phylogenetic analysis revealed threeof 7 known genotypes of HCV includinggenotypes/subtypes 1a (34.5%), 1b (17.2%), 2b (13.8%), 2c (3.6%) and 5a (31.3%). Subtypes 1b and 2b were found among patients with clinical hepatitis, while the single 2c was found among donors. Although subtype 1a was detected among both population, its rate was higher among blood donors (P = 0.003).Subtype 5a was found among the two groups (P= 1. 00).HCV subtypes 1a and 5a are the predominantstrains in Ibadan. The diversity of HCV observed has implications for treatment of patients and design of a broadly protective vaccine against the virus


1. Mora N, Adams WH, Kleithermes S, Dugas L, Balagubramanian N, Sandhu J, Nde H, Small C, Jose J, Scanglione S, Layden JE (2016). A Synthesis of Hepatitis C prevalence estimate in Sub-Saharan Africa: 2000-2013, BMC Infect Dis: 2016 June 13, 160; 283
2. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S (2011).An overview of HCV molecular biology, replication and immune responses. Virology Journal;vol 8.
3. Kapoor A, Simmonds P, Gerold G, Qaisar N, Jain K, Henriquez JA, Firth C, Hirschberg DL, Rice CM, Shields S, Lipkin WI (2011). Characterization of a canine homolog of hepatitis C.
4. Simmonds P (2004). Genetic diversity and evolution of hepatitis C virus-15 years on.Journal of Genera l Virology (2004), 85, 3173-3188.
5. Mukherjee S (2012). Hepatitis C. Medscape.August, 2012.
6. World Health Organization (2012).Viral Hepatitis Factsheet 2012.
7. Rao IB, Johari N, du cros P, Messina J, Ford N, Cooke GS (2015). Hepatitis C Seroprevalence&HIV Co-infection in Sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2015Jul: 15 (7): 8: 819-824
8. Kato N (2000). Genome of Human hepatitis virus (HCV): gene organization, sequence diversity, and variation. Microb. Comp. Genomics 5 (3): 129-51. PMID 11252351
9. Lindenbach BD, Rice CM (2005).Unravelling hepatitis C Virus replication from genome to function.Nature 436: 933-938.
10. Gededzha MP, Selabe SG, Kyaw T, Rakgole JN, Blackard JT, Mphahlele MJ (2012).Introduction of new subtypes and variants of hepatitis C virus genotype 4 in South Africa. J Med Virol. 2012 Apr; 84 (4):601-7.
11.Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM: Structural biology of hepatitis C virus. Hepatology 2004, 39(1):5-19.
12. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky J M, Penin F, Sablon E, Shin I, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.Hepatology 42:962–973. doi:.10.1002/hep.20819.
13. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, Mukaide M, Williams R, Lau JY et al. (2007). New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes Ia, 1b, 2a, 2b,3a, 3b 4,5 and 6a. J Clin Microbiol35 (1): 201-207.
14. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (2014). Global distribution and prevalence of hepatitis C virus genotypes.Hepatology.July 28, 2014.
15. Ramia S and Eid-Fares J (2006). Distribution of hepatitis C virus genotypes in the Middle East.Int J Infect Dis 2006, 10(4):272-277.
16. Forbi JC, Purdi MA, Campo DS, Vaughan G, Dimitrova GE, Ganova-Raeva LM, Xia GL, Khudyakov YE (2012).Epidemic history of hepatitis C virus infection in two remote communities in Nigeria, West Africa. J Gen Virol. 2012 Jul; 93 (Pt 7):1410-21.
17. Markov PV, Pepin J, Frost E, Deslandes S, Labbe A, Pybus OG (2009). Phylogeography and Molecular Epidemiology of Hepatitis C Virus genotype 2 in Africa.Journal of General Virology (2009), 90, 2086-2096.
18. Murphy DG, Sablon E, Chamberland J, Fournier E, Dandavino R, Tremblay CL( 2015). Hepatitis C virus genotype 7, a new genotype originating from Central Africa.J ClinMicrobiol (2015); 53 (3): 967-972
19. Mustapha SK, Bolori MT, Ajayi NA, Nggada HA, Pindiga UH, Gashau W & Khalil MAI ( 2007).Hepatitis C virus antibodies in Nigerians with hepatocellular carcinoma. The Internet Journal of Oncology4.
20. Laraba A, Wadzali G, Sunday B, Abdulfatai O, &Fatai S (2010). Hepatitis C virus infections in Nigerians with chronic liver disease.The Internet Journal of Gastroenterology9.
21. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, Lunel-Fabiani F (2007). Genetic diversity of the hepatitis C vrus: Impact and issues in the antiviral therapy. World J Gastroenterol2007; 13(17): 2416-2426.
22. Kumar S, Stecher G, Tamura (2015). MEGA 7: Molecular Evolutionary Genetic Analysis version 7.0(MEGA 7). Molecular Biology and Evolution(submitted).
23. Saitou N, Nei M (1987).The Neighbor-Joining Method-a new method for reconstructing phylogenetic trees. MolBiolEvol. 4: 406-425.
24. Tamura K and Nei M (1993). Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpazees.Molecular Biology and Evolution 10: 512-526.
25. Tamura K., Nei M., and Kumar S. (2004). Prospects for inferring very large phylogenies by using the neighbor-joining method. Proceedings of the National Academy of Sciences (USA) 101:11030-11035.
26. Kumar S., Stecher G., and Tamura K (2015). MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Molecular Biology and Evolution (submitted).
27. Okwuraiwe, A.P., Salu,O.B., Anomneze, E. Audu, R.A., Ujah, I.A.O(2014).Hepatitis C virus genotypes and viral ribonucleic acid titers in Nigeria.J Gastroenterology, 2014.
28. Oni AO and Harrison TJ (1996).Genotype of hepatitis C Virus in Nigeria.J Med Virol49: 178-186.
29. Naamani KAI, Sinani SAI, Deschenes M (2013). Epidemiology and Treatment of Hepatitis C genotypes 5 and 6.Can J GastroenterolVol 27 No 1 January, 2013.
30. Tamura K and Nei M 1993).Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Molecular Biology 10:512-526
31. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM 2012. Antiviral strategies in hepatitis C virus infection.J Hepatol 56(Suppl 1):S88–S100.
32. Simmonds P (2001). The origin and evolution of hepatitis viruses in humans. 2000 Fleming Lecture. Journal of General Virology (2001), 82: 693-712
33. Otegbayo JA, Taiwo BO, Akingbola TS, Odaibo GN, Adedapo KS, Penugonda S, Adewole FI, Olaleye DO, Murphy R, Kanki P (2008). Prevalence of hepatitis B and C Seropositivity in Nigerian Cohort of HIV-infected Patients.Annals of Hepatology 2008; 7(2): April-June: 152-156.
34. Mohd HK, Groeger J, Flaxman AD, Wiersma ST (2013). Global epidemiology of hepatitis c virus infections: new estimates of age-specific antibody to HCV seroprevalence. Hepatology2013; 57: 1333-1342.
35. Kazmierczak J, Pawelczyk A, Cortes KC, Radkowski M (2013). Seronegative Hepatitis C Virus Infection.Arch.Immunol. Ther.Exp.DOI 10.1007/s00005-013-0257-7.
36. Dhawan VK (2016). Hepatitis C. Medscape, www.
37. Balogun TM, Emmanuel S, Wright KO (2010). Hepatitis C virus co-infection in HIV positive patients.Nig QJ Hosp Med 20, 117-120.
38. Nwankiti OO, Ndako JA, Echeonu GO, Olabode AO, Nwosuh CI, Onovoh EM, Okeke LA, Akinola JO, Duru BN et al (2009). Hepatitis C virus infection in apparently healthy individuals with family history of diabetes in Vom, Plateau state Nigeria. VirolJ 6, 110.
39. Adewole OO, Anteyi E, Ajuwon Z, Wada I, Elegba F, Ahmed P, Betiku Y, Okpe A, Eze S, et al (2009). Hepatitis B and C co-infection in Nigerian patients with HIV infection.J Infect DevCtries 3, 369-375.
40. Onakewhor JU &Okonofua FE (2009).Seroprevalence of Hepatitis c viral antibodies in pregnancy in a tertiary health facility in Nigeria.Niger J ClinPract 12, 65-73.
41. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD (2012). The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.Ann Intern Med. 2012 Feb 21.156(4): 271-8.
42. Davis GL, Balart LA, Schiff ER et al. (1989).Treatment of chronic hepatitis c with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Intervention Therapy Group. N Engl J Med. 1989 Nov. 321(22)151-6.
43. Levrero M (2006).Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene (2006) 25, 3834–3847. doi:10.1038/sj.onc.1209562
Section C (Clinical and Laboratory Research)